Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gwang Ha Kim

Showing results (311-320 of 332) with videos related to

Pageof 34
Sort By:
Plos One|December 14, 2017
Risk factors associated with adverse events during endoscopic ultrasound-guided tissue samplingKwang Hyuck Lee, Eun Young Kim, Juhee Cho, et al.
Gut and Liver|September 10, 2016
Efficacy of Levofloxacin-Based Third-Line Therapy for the Eradication of <i>Helicobacter pylori</i> in Peptic Ulcer DiseaseJoo Hyun Lim, Sang Gyun Kim, Ji Hyun Song, et al.
Neurogastroenterology and Motility|November 26, 2024
Comparison of Tegoprazan and Lansoprazole in Patients With Erosive Esophagitis up to 4 Weeks: A Multi-Center, Randomized, Double-Blind, Active-Comparator Phase 4 TrialCheol Min Shin, Suck Chei Choi, Jin Woong Cho, et al.
BMC Gastroenterology|December 19, 2023
Efficacy and safety of HIP1601 (dual delayed-release esomeprazole) 40 mg in erosive esophagitis compared to HGP1705 (delayed-release esomeprazole) 40 mg: a multicenter, randomized, double-blind, non-inferiority studyHyun Lim, Jong Kyu Park, Hyunsoo Chung, et al.
Gut and Liver|June 22, 2022
A Randomized, Double-Blind, Active-Control, Noninferiority, Multicenter, Phase 4 Study to Evaluate the Efficacy and Safety of Esomeprazole/Sodium Bicarbonate 20/800 mg in Patients with Nonerosive Gastroesophageal Reflux DiseaseSu Hyun Park, Kang Nyeong Lee, Oh Young Lee, et al.
Journal of Neurogastroenterology and Motility|January 28, 2014
Efficacy and Safety of Tiropramide in the Treatment of Patients With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-blind, Non-inferiority Trial, Compared With OctyloniumKang Nyeong Lee, Oh Young Lee, Myung-Gyu Choi, et al.
Gut and Liver|September 12, 2019
Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy as First-Line Treatment for <i>Helicobacter pylori</i> Infection: A Nationwide Randomized Trial in KoreaBeom Jin Kim, Hyuk Lee, Yong Chan Lee, et al.
Journal of Korean Medical Science|August 2, 2016
Online Registry for Nationwide Database of Current Trend of Helicobacter pylori Eradication in Korea: Interim AnalysisBeom Jin Kim, Hyun-Soo Kim, Hyun Joo Song, et al.
Helicobacter|October 17, 2015
Eradication Rates of Helicobacter pylori in Korea Over the Past 10 years and Correlation of the Amount of Antibiotics Use: Nationwide SurveyWoon Geon Shin, Sang Woo Lee, Gwang Ho Baik, et al.
Gut and Liver|February 14, 2025
Evaluation of the Efficacy and Safety of a Dual Delayed-Release Formulation of 10-mg Esomeprazole in Patients with Gastric Erosions: A Multicenter, Randomized, Double-Blind, Active-Control, Phase III StudyHyun Lim, Ju Yup Lee, Yong Hwan Kwon, et al.
Pageof 34

Showing results (311-320 of 332) with videos related to

Sort By:
Pageof 34
Plos One|December 14, 2017
Risk factors associated with adverse events during endoscopic ultrasound-guided tissue samplingKwang Hyuck Lee, Eun Young Kim, Juhee Cho, et al.
Gut and Liver|September 10, 2016
Efficacy of Levofloxacin-Based Third-Line Therapy for the Eradication of <i>Helicobacter pylori</i> in Peptic Ulcer DiseaseJoo Hyun Lim, Sang Gyun Kim, Ji Hyun Song, et al.
Neurogastroenterology and Motility|November 26, 2024
Comparison of Tegoprazan and Lansoprazole in Patients With Erosive Esophagitis up to 4 Weeks: A Multi-Center, Randomized, Double-Blind, Active-Comparator Phase 4 TrialCheol Min Shin, Suck Chei Choi, Jin Woong Cho, et al.
BMC Gastroenterology|December 19, 2023
Efficacy and safety of HIP1601 (dual delayed-release esomeprazole) 40 mg in erosive esophagitis compared to HGP1705 (delayed-release esomeprazole) 40 mg: a multicenter, randomized, double-blind, non-inferiority studyHyun Lim, Jong Kyu Park, Hyunsoo Chung, et al.
Gut and Liver|June 22, 2022
A Randomized, Double-Blind, Active-Control, Noninferiority, Multicenter, Phase 4 Study to Evaluate the Efficacy and Safety of Esomeprazole/Sodium Bicarbonate 20/800 mg in Patients with Nonerosive Gastroesophageal Reflux DiseaseSu Hyun Park, Kang Nyeong Lee, Oh Young Lee, et al.
Journal of Neurogastroenterology and Motility|January 28, 2014
Efficacy and Safety of Tiropramide in the Treatment of Patients With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-blind, Non-inferiority Trial, Compared With OctyloniumKang Nyeong Lee, Oh Young Lee, Myung-Gyu Choi, et al.
Gut and Liver|September 12, 2019
Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy as First-Line Treatment for <i>Helicobacter pylori</i> Infection: A Nationwide Randomized Trial in KoreaBeom Jin Kim, Hyuk Lee, Yong Chan Lee, et al.
Journal of Korean Medical Science|August 2, 2016
Online Registry for Nationwide Database of Current Trend of Helicobacter pylori Eradication in Korea: Interim AnalysisBeom Jin Kim, Hyun-Soo Kim, Hyun Joo Song, et al.
Helicobacter|October 17, 2015
Eradication Rates of Helicobacter pylori in Korea Over the Past 10 years and Correlation of the Amount of Antibiotics Use: Nationwide SurveyWoon Geon Shin, Sang Woo Lee, Gwang Ho Baik, et al.
Gut and Liver|February 14, 2025
Evaluation of the Efficacy and Safety of a Dual Delayed-Release Formulation of 10-mg Esomeprazole in Patients with Gastric Erosions: A Multicenter, Randomized, Double-Blind, Active-Control, Phase III StudyHyun Lim, Ju Yup Lee, Yong Hwan Kwon, et al.
Pageof 34